Histological and clinical characteristics at baseline
| All n=76 | BET1 n=19 | BET2 n=19 | BVS n=19 | PLA n=19 | |
|---|---|---|---|---|---|
| Peak eos/mm2 hpf, mean (SD): | |||||
| Total (derived from 30 hpfs) | 263 (216) | 242 (144) | 290 (188) | 201 (185) | 320 (309) |
| Proximal | 154 (171) | 144 (115) | 149 (109) | 120 (155) | 204 (261) |
| Mid | 186 (197) | 180 (140) | 169 (120) | 153 (209) | 244 (280) |
| Distal | 195 (179) | 195 (129) | 225 (204) | 140 (131) | 217 (228) |
| Mean eos/mm2 hpf, mean (SD): | |||||
| Total (derived from 30 hpfs) | 126 (111) | 122 (79) | 130 (76) | 101 (121) | 153 (153) |
| Proximal | 104 (115) | 92 (69) | 104 (86) | 91 (123) | 130 (161) |
| Mid | 134 (151) | 131 (122) | 124 (105) | 109 (156) | 170 (207) |
| Distal | 142 (128) | 147 (105) | 158 (125) | 105 (108) | 155 (166) |
| Total endoscopic intensity score: mean (SD) | 6.0 (3.1) | 6.7 (2.9) | 5.6 (3.5) | 6.9 (3.2) | 4.8 (2.3) |
| Number (%) of patients with stenosis or solitary rings: | 14 (18.4) | 2 (10.5) | 4 (21.1) | 4 (21.1) | 4 (21.1) |
| Mean diameter of stenosis (mm) | 11 | 10 | 10 | 12 | 11 |
| Dysphagia score, mean (SD) | 4.6 (1.8) | 4.9 (1.4) | 4.2 (2.1) | 4.5 (1.8) | 4.7 (1.9) |
BET1, effervescent tablets for orodispersible use 2×1 mg/day; BET2, effervescent tablets for orodispersible use 2×2 mg/day ; BVS, budesonide viscous suspension 2×5 mL (0.4 mg/mL)/day; eos, eosinophils; hpf, high power field; PLA, placebo.